Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

20161,421 citationsJournal Articlebronze Open Access

Authors

Meletios Α. Dimopoulos · Universidad de Navarra

Albert Oriol · University College London

Hareth Nahi · University College London

Jesús F. San Miguel · Navarre Institute of Health Research

Nizar J. Bahlis · Universidad de Navarra

Saad Z. Usmani · Universidad de Navarra

Neil Rabin ·

Abstract

The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009 .).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 14, pp. 1319-1331

DOI: 10.1056/nejmoa1607751

Field-Weighted Citation Impact: 120.59